Skip to content

Zinc Sulphate Versus Placebo in the Management of Primary Dysmenorrhea

A Comparison of the Efficacy and Safety of 40mg Oral Zinc Sulphate Versus Placebo in the Management of Primary Dysmenorrhea Among Interns in Federal Medical Centre, Asaba: A Triple Blind Randomized Control Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202408820245852
Enrollment
98
Registered
2024-08-30
Start date
2024-12-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary dysmenorrhea

Interventions

oral zinc sulphate
lactose

Sponsors

Orakwe Chukwudumebi Somto
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. young women between the ages of 18-35 years 2. young women who have regular menses (28 + or - 7days) 3. A history of dysmenorrhea for at least 1 day per month i.e. lower abdominal or pelvic pain which occurs for 8- 72hours and is usually associated with the onset of menstrual flow and history of initial onset of dysmenorrhoea 6-12 months after menarche 4. The ability to score pain using a 10cm Visual Analogue Scale (VAS).

Exclusion criteria

Exclusion criteria: 1. Secondary dysmenorrhea 2. A history of chronic or systemic disease 3. A history of adverse reactions to zinc. 4. Who use hormonal medications or contraceptives 5. Those who refuse to participate in the study.

Design outcomes

Primary

MeasureTime frame
Mean pain scores measured over the three cycles using the visual analogue scale

Secondary

MeasureTime frame
The frequency of nausea and vomiting, diarrhoea, anosmia, metallic taste, use of additional analgesics and the frequency of allergic reactions.

Countries

Nigeria

Contacts

Public ContactChukwudumebi Orakwe

Senior registrar

dumebi.orakwe04@gmail.com+2348037383917

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026